Table 1.
Baseline characteristics of the patient groups.
| Paclitaxel DCB (n = 41) | Second-Generation DES (n = 107) | p-Value | |
|---|---|---|---|
| Age | Mean 73.8 ± 11.7 | Mean 69.8 ± 11.1 | 0.048 * |
| Male | 35 (85.4%) | 82 (76.6%) | 0.25 |
| Weight (kg) | 84.39 ± 19.10 | 80.81 ± 14.81 | 0.24 |
| Hypercholesterolaemia | 11 (26.8%) | 26 (24.3%) | 0.82 |
| Hypertension | 23 (56.1%) | 56 (52.3%) | 0.64 |
| PVD | 3 (7.3%) | 5 (4.7%) | 0.52 |
| CVA | 4 (9.8%) | 6 (5.6%) | 0.36 |
| Prior CABG | 1 (2.4%) | 2 (1.9%) | 0.82 |
| Heart Failure | 1 (2.4%) | 3 (2.8%) | 0.91 |
| Previous PCI | 8 (19.5%) | 31 (29%) | 0.21 |
| Prior MI | 9 (22%) | 26 (24.3%) | 0.70 |
| eGFR | Mean 69.88 ± 21.87 | Mean 73.43 ± 23.72 | 0.39 |
| Smoking | 24 (64.9%) | 58 (56.3%) | 0.39 |
| COPD | 3 (7.3%) | 10 (9.3%) | 0.71 |
| Family History of IHD | 4 (9.8%) | 10 (9.3%) | 0.93 |
| Atrial Fibrillation | 5 (12.2%) | 4 (3.7) | 0.052 |
| Diabetes | 13 (31.7%) | 24 (22.4) | 0.23 |
| DAPT 1 month 12 months |
19 (46.3%) 22 (53.7%) |
4 (3.7%) 103 (96.3%) |
<0.01 |
| GPIIbIIIa use | 14 (34.1%) | 20 (18.7%) | 0.06 |
| ACS STEMI NSTEMI |
5 (12.2%) 23 (56.1%) |
10 (9.3%) 47 (43.9%) |
0.37 Ɨ |
| ELECTIVE Stable Angina Staged |
10 (24.4%) 3 (7.3%) |
43 (40.2.9) 7 (6.5%) |
Baseline patient characteristics of patients treated with DCB or DES for de novo LMS. * denotes statistical significance in its composition within the DCB group. Ɨ denotes a p value of a composite of STEMI and NSTEMI vs. angina and staged groups. DAPT: dual antiplatelet therapy; GPIIbIIIa: Glycoprotein IIBIIIa inhibitor.